Evolus (NASDAQ:EOLS) Trading Down 3.8% – Here’s What Happened

Shares of Evolus, Inc. (NASDAQ:EOLS) traded down 3.8% during mid-day trading on Friday . The company traded as low as $12.55 and last traded at $12.55. 226,056 shares were traded during trading, a decline of 62% from the average session volume of 593,329 shares. The stock had previously closed at $13.04.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th. Barclays increased their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Stock Performance

The stock has a market capitalization of $797.84 million, a P/E ratio of -13.95 and a beta of 1.31. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a 50-day moving average of $15.68 and a 200 day moving average of $13.86.

Insider Buying and Selling at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 6.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 2.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of large investors have recently bought and sold shares of the company. Quest Partners LLC bought a new position in Evolus in the second quarter valued at approximately $43,000. Quarry LP bought a new position in shares of Evolus in the 2nd quarter valued at $54,000. Profund Advisors LLC acquired a new position in shares of Evolus during the 2nd quarter worth $130,000. Point72 Asset Management L.P. bought a new stake in shares of Evolus during the 3rd quarter worth $132,000. Finally, Arizona State Retirement System boosted its stake in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after buying an additional 1,253 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.